Company Filing History:
Years Active: 2007
Title: The Innovations of Bradley Dain
Introduction
Bradley Dain is an accomplished inventor based in Hamden, CT (US). He has made significant contributions to the field of genetics, particularly in relation to cognitive responses to treatment for Alzheimer's disease. His work has the potential to impact clinical practices and improve patient outcomes.
Latest Patents
Bradley Dain holds a patent for "CDK5 genetic markers associated with galantamine response." This patent discloses haplotypes in the CDK5 gene that are associated with cognitive responses to galantamine treatment. The patent outlines compositions and methods for detecting and utilizing these CDK5 haplotypes in various clinical applications. These applications include articles of manufacture comprising galantamine or its derivatives, which are approved for treating patients with specific CDK5 haplotypes. Additionally, the patent describes methods and kits for predicting an individual's response to galantamine based on their haplotype profile, as well as methods for treating Alzheimer's patients according to their haplotype profile.
Career Highlights
Bradley Dain is currently associated with Pgxhealth, LLC, where he continues to advance his research and innovations. His work is pivotal in the development of personalized medicine approaches for Alzheimer's treatment.
Collaborations
Some of his notable coworkers include Jeroen Aerssens and Maria Athanasiou, who contribute to the collaborative efforts at Pgxhealth, LLC.
Conclusion
Bradley Dain's innovative work in genetic markers and their applications in Alzheimer's treatment showcases the importance of personalized medicine. His contributions are paving the way for more effective treatment strategies for patients.